Key developments in stem cell therapy in cardiology

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

A novel therapeutic strategy to prevent or reverse ventricular remodeling, the substrate for heart failure and arrhythmias following a myocardial infarction, is the use of cell-based therapy. Successful cell-based tissue regeneration involves a complex orchestration of cellular and molecular events that include stem cell engraftment and differentiation, secretion of anti-inflammatory and angiogenic mediators, and proliferation of endogenous cardiac stem cells. Recent therapeutic approaches involve bone marrow-derived mononuclear cells and mesenchymal stem cells, adipose tissue-derived stem cells, cardiac-derived stem cells and cell combinations. Clinical trials employing mesenchymal stem cells and cardiac-derived stem cells have demonstrated efficacy in infarct size reduction and regional wall contractility improvement. Regarding delivery methods, the safety of catheter-based, transendocardial stem cell injection has been established. These proof-of-concept studies have paved the way for ongoing pivotal trials. Future studies will focus on determining the most efficacious cell type(s) and/or cell combinations and the mechanisms underlying their therapeutic effects.

Original languageEnglish
Pages (from-to)17-24
Number of pages8
JournalRegenerative Medicine
Volume7
Issue number6 SUPPL.
DOIs
StatePublished - Nov 1 2012

Fingerprint

Cardiology
Cell- and Tissue-Based Therapy
Stem cells
Stem Cells
Mesenchymal Stromal Cells
Ventricular Remodeling
Therapeutic Uses
Tissue regeneration
Adipose Tissue
Cardiac Arrhythmias
Catheters
Regeneration
Cell Differentiation
Anti-Inflammatory Agents
Heart Failure
Bone Marrow
Myocardial Infarction
Clinical Trials
Safety
Bone

Keywords

  • Cardiac stem cell
  • Cell transplantation
  • Heart failure
  • Ischemic heart disease
  • Mesenchymal stem cell
  • Myocardial infarction

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Cite this

Key developments in stem cell therapy in cardiology. / Schulman, Ivonne H; Hare, Joshua.

In: Regenerative Medicine, Vol. 7, No. 6 SUPPL., 01.11.2012, p. 17-24.

Research output: Contribution to journalArticle

@article{7f203bc96b3a4a73bb499ad52f5497cb,
title = "Key developments in stem cell therapy in cardiology",
abstract = "A novel therapeutic strategy to prevent or reverse ventricular remodeling, the substrate for heart failure and arrhythmias following a myocardial infarction, is the use of cell-based therapy. Successful cell-based tissue regeneration involves a complex orchestration of cellular and molecular events that include stem cell engraftment and differentiation, secretion of anti-inflammatory and angiogenic mediators, and proliferation of endogenous cardiac stem cells. Recent therapeutic approaches involve bone marrow-derived mononuclear cells and mesenchymal stem cells, adipose tissue-derived stem cells, cardiac-derived stem cells and cell combinations. Clinical trials employing mesenchymal stem cells and cardiac-derived stem cells have demonstrated efficacy in infarct size reduction and regional wall contractility improvement. Regarding delivery methods, the safety of catheter-based, transendocardial stem cell injection has been established. These proof-of-concept studies have paved the way for ongoing pivotal trials. Future studies will focus on determining the most efficacious cell type(s) and/or cell combinations and the mechanisms underlying their therapeutic effects.",
keywords = "Cardiac stem cell, Cell transplantation, Heart failure, Ischemic heart disease, Mesenchymal stem cell, Myocardial infarction",
author = "Schulman, {Ivonne H} and Joshua Hare",
year = "2012",
month = "11",
day = "1",
doi = "10.2217/rme.12.80",
language = "English",
volume = "7",
pages = "17--24",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Key developments in stem cell therapy in cardiology

AU - Schulman, Ivonne H

AU - Hare, Joshua

PY - 2012/11/1

Y1 - 2012/11/1

N2 - A novel therapeutic strategy to prevent or reverse ventricular remodeling, the substrate for heart failure and arrhythmias following a myocardial infarction, is the use of cell-based therapy. Successful cell-based tissue regeneration involves a complex orchestration of cellular and molecular events that include stem cell engraftment and differentiation, secretion of anti-inflammatory and angiogenic mediators, and proliferation of endogenous cardiac stem cells. Recent therapeutic approaches involve bone marrow-derived mononuclear cells and mesenchymal stem cells, adipose tissue-derived stem cells, cardiac-derived stem cells and cell combinations. Clinical trials employing mesenchymal stem cells and cardiac-derived stem cells have demonstrated efficacy in infarct size reduction and regional wall contractility improvement. Regarding delivery methods, the safety of catheter-based, transendocardial stem cell injection has been established. These proof-of-concept studies have paved the way for ongoing pivotal trials. Future studies will focus on determining the most efficacious cell type(s) and/or cell combinations and the mechanisms underlying their therapeutic effects.

AB - A novel therapeutic strategy to prevent or reverse ventricular remodeling, the substrate for heart failure and arrhythmias following a myocardial infarction, is the use of cell-based therapy. Successful cell-based tissue regeneration involves a complex orchestration of cellular and molecular events that include stem cell engraftment and differentiation, secretion of anti-inflammatory and angiogenic mediators, and proliferation of endogenous cardiac stem cells. Recent therapeutic approaches involve bone marrow-derived mononuclear cells and mesenchymal stem cells, adipose tissue-derived stem cells, cardiac-derived stem cells and cell combinations. Clinical trials employing mesenchymal stem cells and cardiac-derived stem cells have demonstrated efficacy in infarct size reduction and regional wall contractility improvement. Regarding delivery methods, the safety of catheter-based, transendocardial stem cell injection has been established. These proof-of-concept studies have paved the way for ongoing pivotal trials. Future studies will focus on determining the most efficacious cell type(s) and/or cell combinations and the mechanisms underlying their therapeutic effects.

KW - Cardiac stem cell

KW - Cell transplantation

KW - Heart failure

KW - Ischemic heart disease

KW - Mesenchymal stem cell

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84870685387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870685387&partnerID=8YFLogxK

U2 - 10.2217/rme.12.80

DO - 10.2217/rme.12.80

M3 - Article

C2 - 23346572

AN - SCOPUS:84870685387

VL - 7

SP - 17

EP - 24

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 6 SUPPL.

ER -